Research programme: cystic fibrosis transmembrane conductance regulator stimulants and inhibitors - University of California San Francisco/Vanda Pharmaceuticals

Drug Profile

Research programme: cystic fibrosis transmembrane conductance regulator stimulants and inhibitors - University of California San Francisco/Vanda Pharmaceuticals

Alternative Names: Cystic fibrosis transmembrane conductance regulator activators - University of California San Francisco/Vanda Pharmaceuticals; Cystic fibrosis transmembrane conductance regulator inhibitors - University of California San Francisco/Vanda Pharmaceuticals

Latest Information Update: 05 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California at San Francisco
  • Class Eye disorder therapies; Laxatives; Urologics
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator inhibitors; Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Constipation; Diarrhoea; Dry eyes; Polycystic kidney disease

Most Recent Events

  • 30 Mar 2017 University of California San Francisco has issued and pending patents pending for cystic fibrosis transmembrane conductance regulator stimulants and inhibitors
  • 30 Mar 2017 Preclinical trials in Constipation in USA (unspecified route) before March 2017
  • 30 Mar 2017 Preclinical trials in Diarrhoea in USA (unspecified route) before March 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top